Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
University of Louisville, Louisville, Kentucky Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville, Tennessee University of Virginia Health System, Charlottesville, Virginia Belgium
Cliniques Universitaires Saint-Luc, Brussels Netherlands
Radboud Universitair Medisch Centrum, Nijmegen